Anteris Technologies Global Corp. · NASDAQ:AVR

Anteris Technologies Global — London Valves 2024

13 slides from Anteris Technologies Global's conference presentation, 2024

  1. Slide 1: DurAVR TAVI: biomimetic design restores flow and leads to significant LV mass regression

    DurAVR® TAVI: biomimetic design restores flow and leads to significant LV mass regression. MRI study Dr. Pankaj Garg University of East Anglia, Norwich, UK

  2. Slide 2: Potential conflicts of interest

    Potential conflicts of interest q I have the following potential conflicts of interest to report: § Consultant fees: Anteris Technologies, Edwards Lifesciences § Participation on Advisory Board: Pie Medical Imaging, Medis Medical Imaging Pcrlondonvalves.com DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAI

  3. Slide 3: DurAVR – A New Class of TAVI

    DurAVR® – A New Class of TAVI Single-piece, native-shaped biomimetic design built to mimic the performance of a healthy aortic valve Pcrlondonvalves.com DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Dev

  4. Slide 4: Over 50 Patients with Small Annuli in Combined Studies

    DurAVR® FIH & EFS: Favorable Hemodynamic Results in Over 50 Patients with Small Annuli in Combined Studies EFS 30 Days (to date) FIH 1 Year (to date) 2.20 2.13 41.0 2.4 49.8 2.00 2.02 2.18 EOA (cm2) & DVI Mean Annulus MPG (mmHg) MPG (mmHg) EOA (cm2) Mean Annulus Diameter: 22.57 mm Diameter: 22.2 mm

  5. Slide 5: Clinical Effects of Laminar Flow vs. Turbulent Flow

    Clinical Effects of Laminar Flow vs. Turbulent Flow Benefits of Consequences of Laminar flow Turbulent flow § Efficient flow and § Abnormal aortic flow reduced afterload  energy loss1,2 § Restoration of laminar § Increased flow may impact the inflammation, workload of the Left thrombosis, and Ventr

  6. Slide 6: LV Mass Impacts Patient's Outcomes

    LV Mass Impacts Patient’s Outcomes § Clinical outcomes after TAVI are correlated to degree of LV Mass regression 1,2 § PARTNER Series (echo assessment) § Higher LVM regression  Better outcomes Clinical Outcomes Between 1 and 5 Years According to Quartiles of Percent Change in LVMi Between Baseline

  7. Slide 7: Currently available AVRs Display Abnormal Flow Patterns

    Currently available AVRs Display Abnormal Flow Patterns Normal Flow-- Impaired Aortic Flow-- Healthy Aortic Valve Sapien 3 Evolut R CEP Magna Ease SFD = 10% SFD = 48% SFD = 25% SFD = 27% FRR = 1% FRR = 35% FRR = 4% FRR = 30% (n=5) Normal Healthy AV Flow vs: TAVI p<0.05 SAVR p<0.01 SFD: Systolic Flow

  8. Slide 8: CMR Study Designed to Evaluate Flow Dynamics of DurAVR and Impact on LV

    CMR Study Designed to Evaluate Flow Dynamics of DurAVR® and Impact on LV § Baseline and 6-month Cardiac Magnetic Resonance (CMR) Imaging incorporating standard cines and 2D contrast acquisition at the ascending aorta § Age- and gender- matched healthy cohort from Norwich (UK) § Root/ascending dimens

  9. Slide 9: Biomimetic DurAVR Restores post-TAVI Laminar Flow Comparable to Healthy Aortic Valve

    Biomimetic DurAVR® Restores post-TAVI Laminar Flow Comparable to Healthy Aortic Valve * * Indexed Systolic Flow Reversal Ratio * * Indexed Systolic Flow Displacement * P<0.05 * P<0.05 (%/cm2) (%/cm2) Pre-intervention DurAVR® THV Healthy Control Pcrlondonvalves.com DurAVR® INVESTIGATIONAL USE ONLY. N

  10. Slide 10: DurAVR THV Improves LV Function at 6 Months

    DurAVR® THV Improves LV Function at 6 Months LV End-Diastolic Volume LV End-Systolic Volume LV Mass (mL) (mL) (g) 250 140 250 120 200 200 P=0.04 P=0.04 P<0.01 100 8% 150 150 80 19% 22% 60 100 100 40 50 50 20 0 0 0 Pre-intervention Post-DurAVR® Pre-intervention Post-DurAVR® Pre-intervention Post-DurA

  11. Slide 11: THV Restores LV Volumes and Function Comparable to Healthy Controls

    DurAVR® THV Restores LV Volumes and Function Comparable to Healthy Controls LV End-Diastolic Volume LV End-Systolic Volume LV Mass (mL) (mL) (g) 250 100 200 200 P=0.95 80 P=0.51 160 P=0.96 150 60 120 100 40 80 50 20 40 0 0 0 Healthy Post-DurAVR® Healthy Post-DurAVR® Healthy Post-DurAVR® (N=20) (N=20

  12. Slide 12: Conclusion

    Conclusion § DurAVR® has demonstrated favourable haemodynamics and safety in FIH/EFS § The DurAVR® Biomimetic System demonstrates: § Restoration of laminar flow similar to individuals with a healthy aortic valve § Early LV reverse remodelling compared with pre-TAVI and similar to healthy controls §

  13. Slide 13: pcronline.com

    pcronline.com

Anteris Technologies Global — London Valves 2024 on 6ix